LRRK2 and melanoma: These data are in contradiction to many studies that have described the association of various gene mutations with an increased cancer risk in PD, such as the association of non-skin cancers with LRRK2 G2019S carriers [266,267], and PD-related genes such as LRRK2, PARKIN and αSyn increasing the risk of melanoma [268].